Methods for purifying FXa variant proteins
US10660946B2 · kind B2 · utility
0Cited by
15References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 4, 2017 |
| Grant date | May 26, 2020 |
| Priority date | — |
| Expiry date | Aug 4, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N9/6432
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions are provided comprising recombinant variants of the human clotting Factor Xa. Such compositions include a wide variety of isoforms and post-translational modifications of FXa and are useful for treating subjects in need of hemostasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.